Lu-Wen Shi (Luwen Shi)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 14

Top Topics

Drug Administration

Childhood Cancer

Top Venues

International journal of health policy and management

The International journal of health planning and management

Journal of clinical pharmacy and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Mengyuan Fu, Zhiwen Gong, Yuezhen Zhu, Can Li, Huangqianyu Li, Lu-Wen Shi, Xiaodong Guan
Disparity in Guideline-Based Antidiabetic Drugs Prescribing for Type 2 Diabetes Patients in Primary Healthcare Facilities Across China, 2017-2019. Pharmacoepidemiology and drug safety 33 (8) (2024)
Yue Zhou, Huseyin Naci, Dingyi Chen, Lin Bai, Lu-Wen Shi, Xiaodong Guan, Anita Katharina Wagner
Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021. BMJ global health 8 (9) (2023)
Xiaoyan Nie, Ruilin Wang, Guangkai Liang, Xinyi Zhang, Ningjia Tang, Yuchun Cai, Congxiao Han, Yuxuan Zhao, Tong Jia, Fang Zhang, Sheng Han, Xiaodong Guan, Lu-Wen Shi, Christine Y Lu
The Impact of Prescribing Monitoring Policy on Drug Use and Expenditures in China: A Multi-center Interrupted Time Series Study. International journal of health policy and management 12 (2023)
Haishaerjiang Wushouer, Lu-Wen Shi, Xiaodong Guan, Yi Min Cui
China starts to pay for pharmaceutical services. Journal of clinical pharmacy and therapeutics 47 (7) (2022)
Cong Huang, Carolina Oi Lam Ung, Haishaerjiang Wushouer, Lin Bai, Xinyi Li, Xiaodong Guan, Lu-Wen Shi
Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis. International journal of health policy and management (2021)
Yichen Zhang, Anita Katharina Wagner, Haoxin Du, Taisen Han, Sumit Gupta, Avram E Denburg, A Lindsay Frazier, Xiaodong Guan, Lu-Wen Shi
Childhood cancer drugs in China: An overview and comparison of regulatory approvals in China and the United States. International journal of cancer 150 (3) (2021)
Haishaerjiang Wushouer, Zhenhuan Luo, Xiaodong Guan, Lu-Wen Shi
Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study. International journal of health policy and management (2020)
Xiaodong Guan, Yichen Zhang, Haishaerjiang Wushouer, Lu-Wen Shi, Dennis Ross-Degnan, Anita Katharina Wagner
Differences in reimbursement listing of anticancer therapies in China: an observational study. BMJ open 10 (1) (2020)
Haijing Guan, Yanan Sheng, Wanjie Guo, Sheng Han, Lu-Wen Shi
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China. Advances in therapy 36 (5) (2019)
Xiaodong Guan, Haishaerjiang Wushouer, Mingchun Yang, Sheng Han, Lu-Wen Shi, Dennis Ross-Degnan, Anita Katharina Wagner
Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. BMJ open 9 (11) (2019)
Xiaodong Guan, Mengyuan Fu, Fanghui Lin, Dawei Zhu, Daniel Vuillermin, Lu-Wen Shi
Burden of visual impairment associated with eye diseases: exploratory survey of 298 Chinese patients. BMJ open 9 (9) (2019)
Xiaodong Guan, Ye Tian, Dennis Ross-Degnan, Chunxia Man, Lu-Wen Shi
Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China. BMJ open 8 (7) (2018)
Xiaodong Guan, Mingchun Yang, Chunxia Man, Ye Tian, Lu-Wen Shi
The effect of the implementation of low price medicine policy on medicine price in China: A retrospective study. The International journal of health planning and management (2018)
Haishaerjiang Wushouer, Ye Tian, Xiao-Dong Guan, Sheng Han, Lu-Wen Shi
Trends and patterns of antibiotic consumption in China's tertiary hospitals: Based on a 5 year surveillance with sales records, 2011-2015. PloS one 12 (12) (2017)